| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11612593 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11612594 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11633387 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11304940 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357764 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11376244 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11426396 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357765 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11622962 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10383864 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US10406143 | AMICUS THERAP US | Methods for treatment of fabry disease |
May, 2027
(3 years from now) | |
| US9987263 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9480682 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9000011 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US11241422 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US11033538 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US10925866 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US9999618 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US10525045 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US8592362 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(5 years from now) | |
| USRE48608 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(5 years from now) | |
| US10813921 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(5 years from now) | |
| US9095584 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(5 years from now) | |
| US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(13 years from now) | |
| US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(13 years from now) | |
| US11458128 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10251873 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10471053 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11666564 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10857141 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10849890 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10849889 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10857142 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10874657 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10874655 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10874656 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10792278 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10792279 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10799491 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10806727 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357761 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357762 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357763 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11389437 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11389436 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278538 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278537 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278536 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278539 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278540 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357784 | AMICUS THERAP US | Use of migalastat for treating Fabry disease in pregnant patients |
Feb, 2039
(15 years from now) | |
| US11642334 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(15 years from now) | |
| US11633388 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(15 years from now) | |
Galafold is owned by Amicus Therap Us.
Galafold contains Migalastat Hydrochloride.
Galafold has a total of 53 drug patents out of which 0 drug patents have expired.
Galafold was authorised for market use on 10 August, 2018.
Galafold is available in capsule;oral dosage forms.
Galafold can be used as a method of reducing podocyte globotriaosylceramide (gl-3) in a fabry patient by administering migalastat; a method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat, the treatment of fabry patients.
Drug patent challenges can be filed against Galafold from 2022-08-10.
The generics of Galafold are possible to be released after 25 March, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 2022-08-10
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients; A method of reducing podocyte globotriaosylceramide (gl-3) in a fabry patient by administering migalastat; A method of reducing left ventricular mass index (lvmi) in a...
Dosage: CAPSULE;ORAL
GALAFOLD family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic